Publications

CTD2 researchers at Dana Farber Cancer Institute identify genome editing by CRISPR-Cas9 and gene suppression by CRISPRi have different off-target effects and combining these approaches provides complementary information in loss-of-function genetic screens.

Review on the emerging paradigm of reactive oxygen species function as specific, intracellular secondary messengers rather than as binary, indiscriminate, damaging molecules in cancer.

CTD2 investigators developed a novel technology which permits fusion gene construction for functional evaluation. Using this methodology, they validated five novel fusion genes as potential drivers for cancer.  

Researchers characterized the role of the transcription repressor ZBTB18 as a putative tumor suppressor in mesenchymal subtype of glioblastoma. 

CTD² scientists surveyed alterations in PI3K/Akt/mTOR pathway across 10,000 human cancers  profiled by TCGA. This study generated a comprehensive and annotated catalog of variants which may serve as a precision medicine approach to stratify patients by mutation type.